67860-41-7

Basic information

• Product Name: 4-(2-Chlorophenyl)-2-iodo-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
• Synonyms: 4-(2-Chlorophenyl)-2-iodo-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
• CAS NO: 67860-41-7
• Molecular Formula: C₁₅H₁₀ClIN₄S
• Molecular Weight: 440.69
• Mol File: 67860-41-7.mol
• Article Data: 1

Chemical Properties

• Melting Point: 254-256 °C
• Boiling Point: 581.4±60.0 °C(Predicted)
• Appearance: /
• Density: 1.95±0.1 g/cm3(Predicted)
• PKA: 2.03±0.40(Predicted)
• CAS DataBase Reference: 4-(2-Chlorophenyl)-2-iodo-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-Chlorophenyl)-2-iodo-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine(67860-41-7)
• EPA Substance Registry System: 4-(2-Chlorophenyl)-2-iodo-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine(67860-41-7)

Safety Data

• Hazardous Substances Data: 67860-41-7(Hazardous Substances Data)

Upstream product

• 67860-46-2 5-(2-chlorophenyl)-2-hydrazino-7-iodo-3H-thieno<2,3-e><1,4>diazepine 
• 78-39-7 Triethyl orthoacetate 
• 36811-58-2 5-(2-chlorophenyl)-1,3-dihydro-2H-thieno[2,3-e][4,1]diazepin-2-one 
• 67860-47-3 5-(2-chlorophenyl)-1,3-dihydro-7-iodo-2H-thieno<2,3-e><1,4>diazepin-2-thione 

Downstream Products

• 125055-10-9 1-[3-[4-(2-Chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl]-2-propynyl]-1,3-dihydro-3-methylquinazolin-2,4(2H,4H)-dione 
• 125030-59-3 4-(2-chlorophenyl)-9-methyl-2[(trimethylsilyl)ethynyl]-6H-thieno[3,2-f][1,2,4]triazolo [4,3-a][1,4]diazepine 
• 125030-45-7 4-(2-Chlorophenyl)-2-[3-(1H-indazol-1-yl)-1-propynyl]-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 
• 125030-41-3 2-[3-(1H-Benzimidazol-1-yl)-1-propynyl]-4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 
• 125048-51-3 4-(2-chlorophenyl)-9-methyl-2-(phenylethynyl)-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]-diazepine 
• 125055-11-0 1-[3-[4-(2-Chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl]-2-propynyl]-1,4-dihydro-2H-3,1-benzoxazin-2-one 
• 125030-70-8 2-[3-(9H-Carbazol-9-yl)-1-propynyl]-4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine dihydrochloride 
• 125031-05-2 Acetic acid 4-(2-chloro-phenyl)-9-methyl-2-[3-(6-oxo-6H-phenanthridin-5-yl)-prop-1-ynyl]-6H-1-thia-5,7,8,9a-tetraaza-cyclopenta[e]azulen-6-yl ester 
• 125031-26-7 5-{3-[4-(2-Chloro-phenyl)-6-hydroxy-9-methyl-6H-1-thia-5,7,8,9a-tetraaza-cyclopenta[e]azulen-2-yl]-prop-2-ynyl}-5H-phenanthridin-6-one 
• 131637-33-7 1-{3-[4-(2-Chloro-5-nitro-phenyl)-9-methyl-6H-1-thia-5,7,8,9a-tetraaza-cyclopenta[e]azulen-2-yl]-prop-2-ynyl}-3,4-dihydro-1H-quinolin-2-one 
• 125031-04-1 5-{3-[4-(2-Chloro-phenyl)-9-methyl-5-oxy-6H-1-thia-5,7,8,9a-tetraaza-cyclopenta[e]azulen-2-yl]-prop-2-ynyl}-5H-phenanthridin-6-one 
• 125055-13-2 1-{3-[4-(2-Chloro-phenyl)-9-methyl-5-oxy-6H-1-thia-5,7,8,9a-tetraaza-cyclopenta[e]azulen-2-yl]-prop-2-ynyl}-3,4-dihydro-1H-quinolin-2-one 
• 125031-16-5 rac-6-acetoxy-4-(2-chlorophenyl)-2-iodo-9-methyl-6H-thieno<3,2-f><1,2,4>triazolo<4,3-a><1,4>diazepine 
• 125031-17-6 rac-4-(2-chlorophenyl)-2-iodo-6-hydroxy-9-methyl-6H-thieno<3,2-f><1,2,4>triazolo<4,3-a><1,4>diazepine 

Relevant articles and documents

Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor

A series of [1,2,4]triazolo[4,3-α][1,4]benzodiazepines bearing an ethynyl functionality at the 8-position and the isosteric thieno[3,2-f][1,2,4]triazolo[4,3-α][1,4]diazepines were prepared and evaluated as antagonists of platelet activating factor. The effects of substitution were explored in in vitro and in vivo test systems designed to measured PAF-antagonistic activity. Results are discussed and compared with previously published data. Many of the compounds had activity superior to WEB 2086, compound 1. In general, the thieno analogues exhibited better oral activity than the corresponding benzodiazepines. The duration of activity upon oral administration was modulated by the substitution on the acetylenic side chain. Compounds 71 and 81 were selected for further pharmacological evaluation as a result of their good oral potency and exceptionally long duration of action.